What did @katelinsaint2016 actually say?
She logged her seventh week on retatrutide and reported losing three pounds, marking three consecutive weeks at that rate. She was upfront that the week was chaotic, including spring break, illness, fewer workouts, and travel. Despite expecting less, she said she was "still on track for losing three pounds a week."
That framing matters. She's implicitly treating a three-pound weekly loss as a baseline expectation, not a lucky result. The video doesn't mention dosing, injection sites, side effects, or prescriber involvement. It's a progress diary, not a clinical breakdown, which shapes what we can and can't fact-check here. What we can assess is whether the weight loss rate she's describing is realistic, typical, or something viewers should interpret carefully.
Does the science back this up?
Three pounds a week is on the high end of what trial data shows, but it's not impossible, especially in early weeks on a GLP-1/GIP/glucagon triple agonist like retatrutide. The phase 2 data is genuinely striking.
The most relevant study is Jastreboff et al. (2023, New England Journal of Medicine), the phase 2 trial of retatrutide in adults with obesity. At the highest dose (12 mg), participants lost an average of 24.2% of body weight over 48 weeks. That works out to roughly 1 to 1.5 lbs per week on average across the full trial period. However, weight loss in GLP-1-class drugs is not linear. Early weeks, especially during dose escalation, can produce faster losses due to appetite suppression, reduced water retention, and caloric deficit stacking. So three pounds a week in week seven is plausible, particularly if she started at a higher body weight.
What the trial data does not support is treating three pounds every week as a stable expectation. Loss rates slow. Plateaus happen. The Jastreboff data shows the curve flattening significantly after week 24.
What did they get wrong (or right)?
She got the transparency right. Acknowledging illness, disrupted workouts, and travel while still reporting accurate scale results is more honest than most weight-loss content on this platform. She didn't claim retatrutide caused the loss independent of diet and exercise, which is a common and misleading oversimplification in peptide content.
What's missing is context that could set viewers up for disappointment. Framing three pounds a week as the expected rate, three weeks running, implies that's the norm. It isn't, based on trial data. Jastreboff et al. (2023) showed meaningful week-to-week variability across participants, and individual response to retatrutide varies based on starting weight, dose, metabolic health, and adherence.
There's also no mention of side effects, which is a real omission. Nausea, vomiting, and GI distress were reported in over 50% of participants in the phase 2 trial, particularly during uptitration. A week-seven video with zero mention of side effects gives viewers an incomplete picture of what this drug actually involves.
What should you actually know?
Retatrutide is not FDA-approved as of mid-2025. It is in phase 3 trials. Anyone currently using it is doing so through a compounded or research-grade source, which means potency, purity, and dosing are not standardized the way they would be with an approved drug. That's not a reason to dismiss it, but it is a reason to be skeptical of clean, simple progress narratives.
The weight loss results in trials are real and significant. But those trials involve controlled dosing, regular monitoring, and reporting of adverse events. Social media updates don't include any of that. Three pounds a week sounds like a win, and it may well be. But viewers watching this as a blueprint should know a few things:
- Weight loss rates on GLP-1-class drugs typically slow after the first 12 to 16 weeks (Jastreboff et al., 2023, NEJM).
- Compounded retatrutide is not equivalent to any approved drug product. Formulation and concentration can vary.
- Sustainable loss on these drugs still requires dietary adherence, which she does mention, to her credit.
- Individual response varies widely. Three pounds a week for one person may be zero for another at the same dose.